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Introduction
Autophagy is a catabolic process ultimately leading to the
degradation of a cell’s own components through the lysosomal
machinery.1,2 During autophagy, portions of the cytoplasm,
protein aggregates or organelles, are sequestered within dou-
ble- or multi-membraned vesicles called autophagosomes, and
subsequently delivered to lysosomes for degradation. The
study of autophagy is now flourishing thanks to the discovery
of the key mechanisms that govern this biological process and
of their roles in physiology. In addition, autophagy is increas-
ingly recognized as having key functions in human diseases
(including cancer) and, therefore, it represents a new arena for
the development of therapeutics. This review presents the
most recent studies addressing the role of autophagy in blood
cancers and in their treatment with the anticipation that both
autophagy inhibition and autophagy activation, depending on
the context, hold promise as a means to treat hematologic
malignancies and to enhance the activity of current therapeu-
tics. In addition, a dedicated section will address the potential
of autophagy-activating approaches (such as fasting or fasting-
mimicking diets) as a means to reduce the side effects of
chemotherapy. These topics shall be discussed after a brief
introduction to the molecular apparatus of autophagy and its
regulators.   
The autophagic machinery
For the purposes of this article we present here a concise
summary of the biology of autophagy, while for a detailed
description of this process we refer the reader to other excel-
lent reviews that have been written on the topic.1,2 Autophagy
begins with the formation of an isolation membrane (also
called the ‘phagophore’), the assembly of which is promoted
by conditions of nutrient, energy or growth factor deprivation
through at least two mechanisms (Figure 1). One is the inhibi-
tion of mTORC1, a multiprotein complex composed of
mTOR, Raptor, mLST8, PRAS40 and DEPTOR which is deput-
ed to couple nutrient and growth factor availability to cell
growth.1,3,4 mTORC1 inhibits autophagy by directly phospho-
rylating ULK proteins on negative sites (Figure 1), but in condi-
tions of nutrient or growth factor deprivation, it becomes inac-
tive and dissociates from ULK1/2, thus leading to its dephos-
phorylation and consequent activation. The second mecha-
nism is represented by the direct phosphorylation, and conse-
quent activation, of ULK1 by adenosine monophosphate-acti-
vated protein kinase (AMPK), an evolutionarily conserved sen-
sor of intracellular AMP/ATP ratio.5,6 ULK1/2 promote
autophagosome formation by regulating the activity of the
Beclin1 interactome.1,2 This multiprotein complex, which
involves Beclin1, the class III phosphoinositide 3-kinase (PI3K)
Vps34, Vps15 and Ambra1, must be assembled in order to
allow the allosteric activation of Vps34, whose lipid kinase
activity is required for autophagy. Two ubiquitin-like protein
conjugation systems (Atg12 and Atg8/LC3) are also required
for the formation of the autophagosome. Atg12 in complex
with Atg5, and with the aid of Atg7 and Atg10, is responsible
for autophagosome nucleation. In the Atg8/LC3 conjugation
system, phosphatidylethanolamine is conjugated to mam-
malian LC3. As a result, LC3 is converted from a soluble form
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Autophagy is a cell recycling process the molecular apparatus of which has been identified over the past decade.
Autophagy allows cells to survive starvation and inhospitable conditions and plays a key role in numerous physio-
logical functions, including hematopoiesis and immune responses. In hematologic malignancies, autophagy can
either act as a chemo-resistance mechanism or have tumor suppressive functions, depending on the context. In addi-
tion, autophagy is involved in other important aspects of blood cancers as it promotes immune competence and anti-
cancer immunity, and may even help enhance patient tolerance to standard treatments. Approaches exploiting
autophagy, either to activate or inhibit it, could find broad application in hematologic malignancies and contribute to
improved clinical outcomes. These aspects are discussed here together with a brief introduction to the molecular
machinery of autophagy and to its role in blood cell physiology.
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named LC3-I to LC3-II, which is stably associated with the
autophagosome membrane and is commonly used to mon-
itor autophagy.7 Several proteins, such as p62/SQSTM1 and
NBR1 (Neighbor of BRCA1), possess an LC3-interacting
region (LIR) and, by interacting with LC3, target precise
structures, including mitochondria, endoplasmic reticulum,
ribosomes, protein aggregates, etc. to the autophagosomes
(selective autophagy). Fully mature autophagosomes fuse
with Rab7-positive endosomes to form amphisomes
which, in turn, fuse with acidic lysosomes to acquire
hydrolytic activity (autophagolysosomes) and degrade their
content.1 Finally, the breakdown products are released into
the cytosol through permeases.
Autophagy is considered to be primarily a cytoprotective
process and a quality control mechanism that removes pro-
tein aggregates and damaged organelles.1,2 Consistent with
this notion, autophagy mediates protective effects in sever-
al mouse models of organ damage, prevents neurodegener-
ation and has a central role in determining the life span of
model organisms. Genetic ablation of key components in
the autophagy apparatus is associated with accelerated
aging, whereas autophagy activation has anti-aging
effects.1,2
Autophagy-activating stimuli and autophagy inhibitors
Many conditions and drugs, including agents in clinical
use, have been reported to activate autophagy. One well-
recognized method to induce autophagy (and probably the
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Figure 1. Schematic model of the autophagic machinery. Autophagy starts with activation of the ULK1/2 kinase complex, which also includes
ATG13 and FIP200. mTORC1, a protein complex that couples nutrient and growth factor availability to cell growth and division, inhibits the
ULK1/2 complex by phosphorylating ULK1 on ‘negative’ sites. Conversely, AMPK (a sensor of energy store depletion that is also activated by
metformin) activates the complex by directly phosphorylating (and consequently activating) ULK1 and by inhibiting mTORC1 (through phos-
phorylation of TSC1/2). Thus, the ULK complex becomes active during starvation, but can also be activated pharmacologically with rapamycin
and its derivatives (i.e. sirolimus and everolimus) or with agents that directly or indirectly reduce PI3K signaling (i.e. TKIs in chronic myeloid
leukemia). Phosphorylated and active ULK1 promotes phosphorylation of Atg13 and FIP200 and dissociates from mTORC1. The PI3K-III
VPS34 is another hub for autophagosome formation, forming a protein complex together with UVRAG, AMBRA1, VPS15, and Beclin1. Atg8
(LC3)-PE and the Atg12/Atg5 conjugation systems, which execute the lipid modification of LC3-I, leading to LC3-II-PE binding to the autophago-
somal membrane, complete autophagosome formation. Autophagosomes’ content, such as proteins and organelles, is readily digested upon
their fusion with lysosomes. The antiapoptotic protein BCL2 prevents the assembly of the Beclin1 interactome by interacting with Beclin1
through its BH3 domain, while the NAD+-dependent deacetylase SIRT1 promotes autophagy by enhancing FOXO3a-dependent transcription of
autophagy genes and by directly de-acetylating Atg proteins. VPS34 inhibitors, such as 3-MA and wortmannin, are effective at inhibiting the
early stages of autophagy, while Bafilomycin A1, CQ, HCQ, and macrolides, such as clarithromycin, block autophagy at later stages by prevent-
ing the fusion of autophagosomes and lysosomes.
most physiological) is by fasting or caloric restriction (a
chronic 10-40% reduction in caloric intake) which activate
autophagy in many organs, including the liver and the cen-
tral nervous system.8,9 Caloric restriction can activate
autophagy through multiple pathways that include: i) inhi-
bition of insulin/IGF-1 signaling with consequent mTORC1
inhibition and ULK1/2 activation; ii) AMPK activation via
increased AMP/ATP ratio (AMPK can subsequently activate
ULK1 directly,5,6 or by inhibiting mTORC1 via TSC1/2); iii)
Beclin1 release from BCL2; and iv) SIRT1 activation (SIRT1
promotes autophagy by deacetylating several Atg factors,
including LC3, and FOXO3a which, in turn, promotes the
transcription of pro-autophagic genes).1,10 Interestingly,
autophagy activation appears to rely on p53 degradation in
human, mouse and nematode cells.11 Different types of
autophagy inducers, including starvation, stimulate protea-
some-mediated p53 removal through the E3 ubiquitin ligase
HDM2. Cytoplasmic, but not nuclear, p53 seems to be
responsible for autophagy inhibition and a possible mecha-
nism is the interaction between p53 and FIP200, an ULK
interacting protein that is required for autophagosome for-
mation in mammalian cells.12,13
Amongst the clinically used drugs, mTORC1 inhibitors,
such as rapamycin, effectively activate autophagy and
recreate some of the beneficial effects of caloric restriction
in model organisms, including life span extension in C. ele-
gans, D. melanogaster, and mice.2 mTORC1 inhibitors also
initiate autophagy in different types of hematologic malig-
nancies, including acute myeloid leukemia (AML), T-cell
acute lymphoblastic leukemia (T-ALL), and lymphoma.3,14-16
As shown in multiple myeloma (MM) cells, autophagy can
be induced by inhibiting PI3K/p110d, which normally pro-
motes AKT and mTORC1 activity, or AKT itself.17,18 In addi-
tion, metformin, an anti-diabetic drug that activates AMPK
and LKB1, has also been shown to activate autophagy in T-
ALL cells.19 Lithium, carbemazepine and valproate, that are
used to treat a range of neurological and psychiatric condi-
tions (and, in the case of sodium valproate, also hematolog-
ic malignancies),20 induce autophagy by activating inositol
monophosphatase (IMPase). IMPase, in turn, activates the
autophagic cascade by reducing the levels of free inositol
and myoinositol-1,4,5-triphosphate (IP3), a second messen-
ger that interferes with autophagy at multiple levels.21
Finally, many other drugs, including agents that are current-
ly used for treating blood cancers (see below), induce
autophagy.
It should be pointed out that the biological and clinical
significance of autophagy activation can vary significantly
depending on whether autophagy is induced in healthy tis-
sues or in cancer cells, and on whether autophagy under-
mines the efficacy of an anticancer agent or, rather, is the
mechanism underlying cancer cell death in response to that
agent. These aspects will be the focus of the next sections.
Pharmacological inhibitors of autophagy include 3-
methyladenine (3-MA) and wortmannin which both block
Vps34 catalytic activity. However, these agents, which are
well suited for experimental autophagy inhibition, cannot
be employed clinically. Namely, the use of 3-MA is limited
by issues of specificity since, at the concentrations used to
inhibit autophagy, this agent can also inhibit class I PI3K
and also affect other kinases, endocytosis, cellular metabo-
lism and mitochondrial transmembrane potential.22 In the
case of wortmannin, its clinical translation is limited by
poor solubility, low stability, and high toxicity.23 Thus,
chloroquine (CQ) and hydroxychloroquine (HCQ) are cur-
rently the most widely used and clinically relevant drugs
that inhibit autophagy. At the cellular level, CQ and HCQ
function primarily by inhibiting lysosomal acidification.24
Cells treated with CQ and HCQ are unable to undergo
lysosomal digestion and exhibit autophagolysosome accu-
mulation in the cytoplasm consistent with blocked
autophagy.7 Interestingly, macrolide antibiotics, such as
bafilomycin A1, azithromycin and clarithromycin also
interfere with autophagy by preventing lysosomal acidifica-
tion and thereby impairing autophagic degradation.25
Clarithromycin was reported to halt autophagy after fusion
of autophagosomes with lysosomes in multiple myeloma
cells.26 More recently, autophagy inhibition in response to
this antibiotic has also been reported in K562 chronic
myeloid leukemia (CML) cells.27 Finally, the immunosup-
pressant FTY720 (a synthetic sphingosine analog which is
approved for the treatment of multiple sclerosis) also
appears to block the autophagic flux and to cause accumu-
lation of autophagolysosomes and increased LC3-II and p62
levels.28
The role of autophagy in hematopoiesis 
and immune control
The autophagic machinery has been shown to play a fun-
damental role in key physiological processes including
hematopoiesis and immunity. Liu and colleagues found that
conditional deletion of FIP200 in hematopoietic stem cells
(HSC) leads to perinatal lethality and severe anemia.29
FIP200 appears to be required in a cell-autonomous fashion
for the maintenance and function of fetal HSCs. Its ablation
does not cause HSC apoptosis, but rather increases HSC
proliferation and this effect is accompanied by accumula-
tion of mitochondria and production of reactive oxygen
species. A similar phenotype was observed upon genetic
deletion of Atg7, an E1-like enzyme with a key role in both
the Atg12 and Atg8/LC3 conjugation systems.30 Atg7 dele-
tion in mice disrupts normal HSC functions leading to
severe myeloproliferation, resembling human myelodys-
plastic syndrome, and death within weeks. In addition,
Atg7 deficiency causes defective removal of mitochondria
in erythroid cells, severe anemia, and a severe impairment
of degranulation in mast cells.31,32 Ulk1 was also found to
play a role in the autophagic clearance of mitochondria and
ribosomes during reticulocyte maturation.33
Autophagy is also involved in immune competence and
pathogen clearance by contributing to: i) the elimination of
intracellular microbes; ii) activation of the inflammasome
and consequent secretion of cytokines, such as IL-1b and
IL8: iii) regulatory interactions of Toll-like receptors and
Nod-like receptors; iv) antigen presentation; and v) T-cell
development and homeostasis.34 Pua and colleagues found
that Atg5-deficient T lymphocytes undergo full maturation,
but the numbers of total thymocytes and peripheral T and
B lymphocytes are reduced in Atg5 chimeras.35 In peripheral
lymphoid organs, Atg5-/- CD8+ T lymphocytes show
increased cell death. In addition, Atg5-/- CD4+ and CD8+ T
cells exhibit impaired proliferation after T-cell receptor
stimulation. Therefore, these results suggest that autophagy
may be essential for both T-lymphocyte survival and prolif-
eration, and highlight the importance of autophagy in
immune responses.
Autophagy in blood cancers
The role of autophagy in cancer treatment is double
faced. On the one hand, autophagy can be the driving force
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for the maintenance of defined cancer cell compartments,
such as leukemia stem cells, or act as a drug resistance
mechanism promoting cancer cell survival via self-diges-
tion. On the other hand, autophagy can provide an effective
tumor suppressive mechanism, permit effective antitumor
immunity and, possibly, help protect healthy tissues from
the toxicity of cancer treatments (see below). Thus, while in
certain contexts autophagy inhibition is desirable, in others,
its activation may be more beneficial. We are going to pres-
ent both the rationales for inhibiting autophagy in treating
hematologic malignancies and those for activating it, and
discuss the contexts in which one type of intervention may
be preferable to the other. 
Rationales for inhibiting autophagy in hematologic malig-
nancies  
There is a strong rationale for the use of autophagy
inhibitors in cancer treatment when autophagy acts as a
mechanism that helps cancer cells recover from the insult of
anticancer treatments. For instance, autophagy is activated
in response to DNA damaging agents and counteracts their
activity by increasing bioenergetics and by avoiding apop-
tosis.36,37 A list of agents whose activity in cancer cells is
reduced by autophagy (as detected in pre-clinical assays) is
presented in Table 1. In all of these instances, inhibiting
autophagy (either pharmacologically or by selective silenc-
ing of key components of the autophagic machinery) was
reported to enhance the activity of the anticancer agent. Of
particular interest in this context is the use of autophagy
inhibitors CML. Tyrosine kinase inhibitors (TKIs), such as
imatinib, dasatinib or nilotinib, that currently represent the
gold standard of CML treatment,50 stimulate autophagy in
CML cells, likely through inhibition of the PI3K-AKT-
mTORC1 axis.51 In turn, autophagy promotes survival and
leukemogenic potential of CML stem cells30,52 which are
insensitive to TKIs53,54 and are considered to be responsible
for disease relapses after TKI discontinuation.50 We demon-
strated that suppression of autophagy, using either pharma-
cological inhibitors or silencing of essential autophagy
genes, enhanced cell death induced by imatinib in cell lines
and primary CML cells.38,50 Moreover, the combination of
imatinib, nilotinib, or dasatinib with CQ-mediated
autophagy inhibition, resulted in near complete elimination
of phenotypically and functionally defined CML stem cells.
Additional experiments have meanwhile confirmed the
potential of autophagy inhibition as a strategy to strengthen
the activity of TKIs in CML.27,39 Thus, autophagy inhibitors,
combined with TKIs, could become an approach to
improve clinical outcomes in CML and increase the cure
rate for patients.
Another application of great interest for autophagy
inhibitors is linked to their capacity to increase the exposure
of target antigens at the surface of cancer cells. For instance,
Alinari and colleagues found that, by blocking autophagic
flux, FTY720 prevents lysosome-dependent degradation of
the therapeutic target, CD74.55 As a result, FTY720 sensi-
tizes mantle cell lymphoma cells to milatuzumab, an anti-
CD74 monoclonal antibody. Whether such an approach
could also be used to increase the efficacy of other mono-
clonal antibodies, such as rituximab in non-Hodgkin’s lym-
phomas and in B-cell chronic lymphocytic leukemia (B-
CLL), still remains to be shown. 
Finally, it should be highlighted that autophagy inhibitors
also have anti-angiogenic properties due to their interfer-
ence with endothelial cell survival and capacity to form cap-
illary-like structures.56,57 Therefore, in the light of the pro-
posed role of angiogenesis in hematologic cancers, includ-
ing multiple myeloma (MM), leukemias and lymphomas,58-
60 another mechanism through which autophagy inhibitors
could be beneficial is by affecting cancer cell vasculature.
Clinical experience with autophagy inhibitors 
in blood cancers
HCQ and CQ are currently being evaluated as single
agents or in combination with conventional therapeutics or
molecularly-targeted small molecule inhibitors in many
types of cancer,61 and trials in hematologic malignancies
have also begun. These include studies of patients with
CML (NCT01227135; imatinib ± HQC) and MM
(NCT01396200; cyclophosphamide + dexamethasone +
HCQ; NCT01438177, cyclophosphamide + bortezomib +
CQ; NCT00568880, bortezomib + HCQ).
The serendipitous observation by our groups that adding
clarithromycin to TKIs induced disease remission in CML
A. Nencioni et al.
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Table 1. Agents for which autophagy acts as a resistance mechanism.
Disease Drug/intervention Experimental approach used to inhibit autophagy Reference
CML imatinib CQ, bafilomycin A1, Atg5/Atg7 silencing, Bellodi et al.38 Drullion et al.39
CML dasatinib clarithromycin Schafranek et al.27
CML suberoylanilide hydroxamic acid (SAHA) CQ Carew et al.40
CML perifosine CQ Tong et al.41
AML daunorubicin CQ, Atg5/Atg7 silencing Han et al.42
AML obatoclax (BH3 mimetic) 3-MA, CQ, bafilomycin A1 Rahmani et al.43
AML vitamin D3 Beclin1 silencing Wang et al.44
APL ATRA Beclin1 silencing Trocoli et al.45
MM doxorubicin, melphalan HCQ, 3-MA, Beclin1/Atg5 silencing Han et al.42
MM sorafenib CQ, 3-MA Kharaziha et al.46
NHL dual AKT-mTOR inhibition HCQ, Atg gene silencing Rosich et al.47
NHL cyclophosphamide, MNNG, p53 reactivation CQ, Atg5 silencing Amaravadi et al.36
B-CLL dasatinib 3-MA, CQ Amrein et al.48
T-ALL TRAIL 3-MA, wortmannin, LY294002 Zoppoli et al.49
APL: acute promyelocytic leukemia; NHL: non-Hodgkin’s lymphoma; B-CLL: B-cell chronic lymphocytic leukemia.
patients who were otherwise refractory to TKIs is highly
promising and suggests that autophagy inhibition could
actually be a viable strategy to enhance the activity of TKIs
in CML.62 In particular, these clinical observations are
strengthened by an in vitro study confirming that this
macrolide indeed blocks autophagy in CML cells and
potentiates the anti-leukemic activity of TKIs.27
Nonetheless, further studies are required to confirm that the
benefit to patients of adding clarithromycin to TKIs is
indeed due to autophagy inhibition and not to other mech-
anisms, such as the propensity of macrolides to inhibit
cytochrome CYP3A4 in the liver leading to increased TKI
levels (AM Carella, unpublished data, 2011).63
Autophagy as a tumor suppressive mechanism 
and autophagy-activating agents with activity against
blood cancers
Although autophagy inhibition holds promise for treating
hematologic malignancies based on the rationales described
above, there is another side to the coin, reflecting the view
of the role of autophagy as a tumor suppressive mecha-
nism. Such a role is supported by accumulating evidence
and suggests that autophagy activation could also be a
viable approach for treating cancer, at least in certain con-
texts and with well-defined measures (Figure 2). Beclin1 is a
tumor suppressor and is frequently monoallelically lost in
breast, prostate and ovarian cancer.64,65 In addition,
autophagy is probably frequently dampened in cancer cells
due to mutations in the PI3K-AKT-mTORC1 pathway that
render this signaling cascade constitutively active.66 In this
context, Wang and co-workers recently established that
Beclin1 is a direct target of AKT which phosphorylates it on
specific sites thereby generating binding sites for the protein
14-3-3.67 As a result, Beclin1 is sequestered to the cytoskele-
ton, its interaction with Vps34 is prevented and, conse-
quently, autophagy is reduced. It is also well-established
that caloric restriction, well-known to activate autophagy,2
reduces cancer incidence in animal models, including mon-
keys.68,69 Strikingly, fasting (another measure that potently
stimulates autophagy),70 was recently shown to be suffi-
cient to promote cancer regressions and to enhance the
activity of chemotherapy in animal models, although
whether this effect relies, at least partially, on autophagy
induction in vivo remains unproven.71,72 In an attempt to
explain how autophagy could carry out its anticancer activ-
ity, it was initially proposed that sustained cellular self-can-
nibalism could impair cancer cell proliferation.11 More
recently, Liu and colleagues found that the Beclin1 interac-
tome is involved in ensuring p53 stability and function.73 A
reduction in Beclin1 levels was found to impair the stability
of the two de-ubiquitinating enzymes USP10 and USP13,
which have p53 among their targets. As a result, Beclin1
loss would translate into p53 degradation. Consistent with
a contribution of p53 deficiency to tumorigenesis induced
by Beclin1 deletion, the tumor spectra of p53+/- and
Beclin1+/- mice strongly overlap, with the highest frequen-
cies of tumors in both mouse strains being lymphoma, lung
carcinoma, and hepatoma.74
It is also possible, although highly controversial, that in
well-defined circumstances, autophagy could turn into a
true cell death program (‘autophagic cell death’) instead of
being cytoprotective. Such a function for autophagy could
be designed to eliminate malignant cells since it appears to
become active in response to oncogenic stress. Cell transfor-
mation with oncogenic HRAS was shown to lead to the
upregulation of the BH3-only protein Noxa, as well as of
Beclin1.75 In response to HRAS, Noxa displaces Beclin1 from
MCL1 leading to autophagy activation and autophagic cell
death, with the result of limiting clonogenic expansion of
transformed cells. Similarly, autophagic cell death was also
reported in response to transformation with Myc upon con-
comitant Aurora kinase inhibition.76 Many anticancer
agents were also reported to use autophagy to kill cancer
cells, as indicated by the finding that autophagy inhibition
reduces, instead of enhancing, their efficacy (Table 2).
Interestingly, in the case of autophagic cell death of MM
cells in response to FK866 (a nicotinamide phosphoribosyl-
transferase inhibitor that lowers NAD+), autophagy appears
to be triggered via both transcription-dependent (through
TFEB, a master regulator of lysosomal biogenesis that is
activated in response to nutrient deprivation via ERK2)  and
transcription-independent mechanisms (via PI3K/mTORC1
inhibition).86 For all of these agents, autophagy activation
could be a determining factor in their efficacy.
More detailed information as to how autophagy can turn
from a protective mechanism into a cell death program is
likely to be forthcoming in the future. However, a link
between proteins from the autophagy apparatus and apop-
totic cascades has already been illustrated. Rubinstein and
colleagues identified Atg12 as a positive mediator of mito-
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Figure 2. Regulation of autophagy by oncogenes and tumor suppres-
sors. Strong evidence suggests that autophagy could act as a tumor
suppressive mechanism. Beclin1 is a tumor suppressor and its dele-
tion in Beclin1+/- mice leads to a cancer phenotype that resembles
the one observed with p53+/- mice. In addition, many well-known
tumor suppressors (in blue insets) promote autophagy, while many
oncogenes (in red insets) are responsible for autophagy inhibition.
The oncogenes PI3K and AKT inhibit autophagy by activating
mTORC1. In addition, AKT also inhibits autophagy by directly phos-
phorylating Beclin1, thus promoting its interaction with 14-3-3 pro-
teins and its sequestration at the level of vimentin filaments in the
cytoskeleton. BCL2 and BCLxL (which are frequently over-expressed
in human cancers, including lymphoid leukemias and lymphomas)
inhibit autophagy by binding to Beclin1. Tumor suppressors such as
PTEN, TSC1/2, and LKB1 activate autophagy by inhibiting mTORC1.
Several mechanisms have been proposed through which autophagy
could contribute to oppose carcinogenesis. They include p53 stabi-
lization, increased genome stability, activation of the mitochondrial
apoptotic pathway, ‘autophagic cell death’ in cancer cells (either in
response to defined agents or to oncogenic transformation), and/or
enhancement of antitumor immunity. 
chondrial apoptosis by showing that this protein binds and
inactivates the anti-apoptotic BCL2 family members BCL2
and MCL1.87 In their hands, knockdown of Atg12 inhibited
Bax activation and cytochrome c release, while Atg12 over-
expression antagonized MCL1 anti-apoptotic function. In
addition, Radoshevich et al. demonstrated that Atg12 forms
a complex with Atg3 by binding it on a specific residue and
that such a complex is a requirement for mitochondrial cell
death.88
Last but not least, the mechanism (or one of the mecha-
nisms) through which autophagy could exert its anticancer
activity is by favoring tumor rejection by the immune sys-
tem. The role of autophagy in antigen presentation and in
immune function is well-established.34 In particular, studies
show how autophagy plays a pivotal role in tumor antigen
cross-presentation (priming of CD8+ cytotoxic T cells by
soluble antigens/cell-derived materials via antigen present-
ing cells).89,90 Interestingly, Ramakrishnan and colleagues
found that chemotherapy-induced autophagy may also
favor tumor immune rejection by promoting mannose-6-
phosphate receptor accumulation at the cancer cell sur-
face.91 Indeed, mannose-6-phosphate receptor accumulation
at the tumor cell surface during chemotherapy was
observed in several mouse tumor models and in MM
patients.
Given this, concerns have been raised that autophagy
inhibition may hamper antitumor immune reactions and
the use of autophagy inhibitors may not be appropriate in
the context of treatment approaches that exploit the
immune system.61
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Figure 3. Schematic repre-
sentation of possible advan-
tages of inhibiting versus
activating autophagy in the
treatment of blood cancers.
Increased activity of differ-
ent types of anticancer
agents (including many
chemotherapeutics and
TKIs), eradication of the
CML stem cell compart-
ment, exposure of antigens
(i.e. CD74) at the surface of
lymphoma cells for anti-
body-mediated therapies,
as well as anti-angiogenic
effects are amongst the
benefits of autophagy inhibi-
tion. Autophagic cell death
in cancer cells in response
to defined agents, activation
of a tumor suppressive
apparatus, increased
immune defenses and
immune-mediated cancer
rejection, as well as, possi-
bly, protection from the toxi-
city of cancer treatments
are the predicted advan-
tages of autophagy-activat-
ing interventions. 
Table 2. Agents that were reported to induce autophagic cell death.
Disease Drug/intervention Experimental approach used to inhibit autophagy Reference
CML resveratrol p62 silencing Puissant et al.77
CML lapatinib 3-MA, Beclin1/Atg5/Atg7 silencing Huang et al.78
CML arsenic trioxide Beclin1/Atg7/p62 silencing Goussetis et al.79
AML FK866 3-MA, wortmannin, LY294002 Nahimana et al.80
APL ATRA bafilomycin A1, 3-MA, ULK1 silencing Isakson et al.81
MDS arsenic trioxide 3-MA Qian et al.82
T-ALL TNFα 3-MA Jia et al.83
T-ALL arsenic trioxide 3-MA Qian et al.82
T-ALL FK866 3-MA, wortmannin, LY294002 Zoppoli et al.49,80
MM compound A (Skp2 inhibitor) bafilomycin A1 Chen Q et al.84
MDS: myelodysplastic syndrome.
Can autophagy activation reduce 
treatment-related toxicities?
Treatment-related toxicities are a major issue in the
approach to patients with hematologic cancers (and with
cancer in general) as they significantly affect patient Quality
of Life, can be severe enough to require hospitalization, and
not infrequently lead to patient death. Therefore, there is a
search for approaches that reduce the side effects of com-
monly used therapeutics since such approaches have a
potentially huge impact on medical practice. In this context,
theoretically, the protective action of autophagy could be
exploited as a means to alleviate the effects of cancer treat-
ment on healthy tissues while simultaneously achieving
some anticancer activity. Preliminary evidence shows that
autophagy, as induced with rapamycin, could confer neuro-
protection in response to proteasome inhibition.92 This
could be interesting since proteasome inhibitors, such as
bortezomib, are now commonly used in treatment of MM
and are also being evaluated for applications in immune-
mediated disorders.93,94 However, neurotoxicity remains a
major side effect of these agents and one that frequently
limits their use.
Short courses of fasting, which is known to activate
autophagy,70 show remarkable protective activity from
chemotherapy-induced toxicity in pre-clinical models and
preliminary clinical data indicate that fasting may also be
effective in humans.95-98 Importantly, while healthy cells
adapt to starvation by reverting to a self-protection mode,
cancer cells appear to be less efficient at responding to star-
vation, possibly due to the aberrant activation of growth-
promoting signaling cascades.71,72,99 In fact, starved cancer
cells become even more prone to oxidative stress and more
sensitive to chemo-radiotherapy.71,72 Noticeably, the benefits
of short-term starvation in chemoprotection and in the
delay of tumor progression are well supported on a pre-clin-
ical level and are also suggested by initial clinical observa-
tions. However, the benefits of chronic calorie restriction, or
even of short-term calorie and/or macronutrient restriction,
are not so clear.98
Several clinical studies being conducted at American and
European institutions are currently evaluating fasting as a
means to improve the tolerability of chemotherapy
(NCT01304251, NCT01175837, NCT00936364,
NCT01175837). It is still not known whether the protection
induced by fasting is to be ascribed (completely or partially)
to autophagy induction in healthy tissues. However, these
ongoing studies  do suggest that at least one autophagy-
inducing measure may be effective in reducing the toxicity
of chemotherapy.
Conclusions 
Results from the first clinical studies of autophagy
inhibitors for the treatment of hematologic malignancies
should soon be available and will shed light on the toxicity
and efficacy of this type of agent. Efforts are also being
made to identify new autophagy inhibitors which could
have better pharmacological properties, better tolerance
and, possibly, improved activity.100 In the meantime, appli-
cations for autophagy activating strategies are also being
envisaged, either in terms of cancer prevention, or as a way
to kill cancer cells by turning autophagy into a deadly mech-
anism. The finding that both autophagy inhibition and
autophagy activation can have anticancer effects is only
apparently contradictory, since it clearly reflects the com-
plexity of cancers and of their different presentations. It also
reflects the possibility of targeting different aspects of can-
cer biology by means that are sometimes the opposite of
one another.
Although it still has to be definitively proven, it is possible
that autophagy-activating pharmacological or dietary
approaches could help reduce some of the side effects of
anticancer agents. Finally, autophagy induction could be
exploited as a way to enhance the efficacy of anticancer
immune responses that arise either spontaneously (perhaps
favored by chemotherapy) or in response to anticancer vac-
cinations (Figure 3).
In conclusion, we predict that in the near future we will
see several autophagy modulating approaches (either phar-
macological or dietary) become part of our clinical practice
both as physicians and as hematologists.
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